I 2, 12- ugers, dobbeltblinde endoskopiundersøgelser, var den kummulative incidens af gastroduodenal ulceration signifikant lavere hos patienter behandlet med etoricoxib 120 mg én gang daglig, end hos patienter behandlet med enten naproxen 500 mg 2 gange daglig eller ibuprofen 800 mg 3 gange daglig.
In two 12-week double-blind endoscopy studies, the cumulative incidence of gastroduodenal ulceration was significantly lower in patients treated with etoricoxib 120 mg once daily than in patients treated with either naproxen 500 mg twice daily or ibuprofen 800 mg three times daily.